Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

03 April 2019 : Original article  

Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

Cheng-ying Zhu12BCDEFG, Sha-sha Zhao2B, Xiao-kai Wang3BCE, Li Wang4BC, Fei-yan Wang1CD, Shu Fang2EF, Zhan-xiang Liu2B, Li-xun Guan2D, Yu-chen Liu2D, Yi Ding2E, Li-ping Dou2D, Li-li Wang2D, Chun-ji Gao12FG*

DOI: 10.12659/AOT.914101

Ann Transplant 2019; 24:175-184

Abstract

BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication following solid organ transplantation and allogeneic hematopoietic stem cell transplantation (Allo-HSCT), which gives rise to high mortality rates.

MATERIAL AND METHODS: This was a single-center retrospective analysis based on 27 patients who were diagnosed with PTLD following Allo-HSCT between January 1, 2007 and June 2018 at the Chinese PLA General Hospital. The purpose of this analysis was to investigate responses and prognostic factors of rituximab-based treatment.

RESULTS: Twenty-seven patients were treated with rituximab. Among them, 20 of 27 patients (74.07%) had a complete response, 2 of 27 patients (7.41%) had a partial response, 5 of 27 patients (18.52%) had no response, and 22 of 27 patients (81.48%) cleared Epstein-Barr virus (EBV) copies. There were no obvious side effects. The 1-year overall survival (OS) estimate was 46.8% (95% CI, 23.1–65.5%). Univariate analysis revealed that lower OS was correlated with Eastern Cooperative Oncology Group (ECOG) score standard (3–4), Epstein-Barr virus (EBV) viral load (≥10⁶ copies/mL), bacteria or fungal infection, and EBV reactivation were positive after treatment with 1 or 2 doses of rituximab (P<0.05). Multivariate analysis showed that each of the following were independently associated with lower OS (P<0.05): female, ECOG score standard (3–4), and EBV reactivation were positive after treatment with 1 or 2 doses of rituximab.

CONCLUSIONS: Our results demonstrated that rituximab-based treatment was a safe and effective strategy for patients who were diagnosed with PTLD following Allo-HSCT. The identified prognostic factors may help to detect which PTLD patients are at a higher risk of mortality.

Keywords: Epstein-Barr Virus Infections, Graft vs Host Disease, Lymphoproliferative Disorders, Transplants, Adolescent, Antineoplastic Agents, Immunological, Child, DNA, Viral, Postoperative Complications, Proportional Hazards Models, rituximab, Time Factors, Transplantation, Homologous, Viral Load, Virus Activation, young adult

Add Comment 0 Comments

In Press

Original article  

Outcomes of Combined Liver-Kidney Transplantation in Polycystic Liver and Kidney Disease

Ann Transplant In Press; DOI: 10.12659/AOT.947639  

Most Viewed Current Articles

03 Jan 2023 : Original article   6,893

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...

DOI :10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

15 Aug 2023 : Review article   6,848

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

DOI :10.12659/AOT.939750

Ann Transplant 2023; 28:e939750

16 May 2023 : Original article   6,597

Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...

DOI :10.12659/AOT.939258

Ann Transplant 2023; 28:e939258

28 May 2024 : Original article   5,949

Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...

DOI :10.12659/AOT.943281

Ann Transplant 2024; 29:e943281

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358